Fredun Pharmaceuticals share price
NSE: FREDUNBSE: 539730Pharmaceuticals & BiotechnologySmall Cap
Fredun Pharmaceuticals Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Mar 2016
Last close ₹1,367.00down ₹86.50 (5.95%)BSE ₹1,366.05
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,453.50.
30 Oct: open ₹1,455.00, high ₹1,467.90, low ₹1,360.00
52-week range of BSE trades to 30 Oct 2026
₹454.05Low, 12 Jan 2026₹1,666.35High, 8 Oct 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹2,310 Cr1,474th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 8.31
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.02%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 18.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.80
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 53,67255.3% delivered
Results
Standalone, as consolidated accounts are on record for only 2 of the last ten years; ₹ crore.Fredun Pharmaceuticals quarterly results
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹228 Crup 8.24%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹13 Crup 19.00%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 5.8%
Revenue by quarter
Peak revenue ₹228 Cr, quarter to Jun 2026; lowest ₹102 Cr, quarter to Dec 2024
Net profit by quarter, a loss in red
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 107 | 102 | 165 | 119 | 144 | 160 | 210 | 228 |
| Net profit | 4 | 5 | 7 | 7 | 10 | 10 | 11 | 13 |
| Net margin | 4.0% | 5.2% | 4.3% | 5.7% | 6.8% | 6.6% | 5.3% | 5.8% |
Standalone. The last eight quarters. The latest is shaded.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹633 Crup 40.21%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹33 Crup 59.59%
- Net margin
- 5.2%
Revenue by year
Peak revenue ₹633 Cr, year to Mar 2026; lowest ₹58 Cr, year to Mar 2018
Net profit by year, a loss in red
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 59 | 58 | 95 | 110 | 132 | 222 | 274 | 347 | 452 | 633 |
| Net profit | 1 | 2 | 4 | 8 | 2 | 6 | 11 | 16 | 21 | 33 |
| Net margin | 2.4% | 3.0% | 4.7% | 7.1% | 1.5% | 2.9% | 3.9% | 4.5% | 4.6% | 5.2% |
Standalone. Years to March. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, The Company is in segment of manufacturing pharmaceuticals products, which carries all its revenue.
Valuation
Today, against the company's own history. Not shown, P/E: a results filing in the last twelve months restated the quarters before it inside its year to date, so the four quarters as the company reported them do not add to a twelve-month profit; the ratio returns once the trailing year no longer holds a quarter from before the restatement.Fredun Pharmaceuticals PE ratio and valuation
Price to book
At or below today's level on 97% of 1,763 trading days since Nov 2018.
LowestHighest
Its median3.85Industry median2.88
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 13% of 2,176 trading days over the last 10 years.
LowestHighest
Its median0.10%Industry median0.49%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +150.1% | +37.7% | +81.6% | 0.0% |
| 3 years | +29.2% | +36.5% | −5.5% | 0.1% |
| 5 years | +29.3% | +64.4% | −21.4% | 0.1% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 1, 3 and 5 years is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count. Earnings growth over 5 years includes one-off items (exceptional items and the result of businesses sold or closed) of more than a tenth of the profit of the year to Mar 2021.
Mutual fund holdings
2 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before.
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 2
| Fund | |||
|---|---|---|---|
 Motilal Oswal BSE Healthcare ETFMotilal Oswal Mutual Fund | 198 | 0.06% | ₹0.03 Cr |
 Bandhan BSE Healthcare Index FundBandhan Mutual Fund | 93 | 0.06% | ₹0.01 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 2 Nov 2025.Fredun Pharmaceuticals insider trading
No promoter, director, key manager or employee bought or sold on the market.
- Promoters and promoter group: no market trade · 2 off-market moves
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Fredun Pharmaceuticals competitors and peers
Pharmaceuticals, 215 listed companies, priced on 30 Oct 2026. The table lists the 8 companies closest to Fredun Pharmaceuticals in market cap.Healthcare companies
Fredun Pharmaceuticals is not on the chart: it has no P/E or return on equity today
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Shukra PharmaceuticalsSHUKRAPHAR | 3,291 | 91.31 | 36.63 | +115.0% | +256.2% | 47.2% | 47.3% | 0.01% |
 Ind-Swift LaboratoriesINDSWFTLAB | 3,202 | 38.32 | 2.17 | +66.4% | – | 6.0% | 4.8% | 0.00% |
 Solara Active Pharma SciencesSOLARA | 3,052 | 82.63 | 2.13 | +27.3% | – | 2.7% | 6.4% | 0.00% |
 HikalHIKAL | 2,609 | – | 2.18 | −5.4% | −153.4% | −2.7% | 3.5% | 0.28% |
 Sai ParenteralsSAIPARENT | 2,306 | 92.50 | 4.65 | – | – | 5.0% | 4.5% | 0.00% |
 Dishman Carbogen AmcisDCAL | 2,274 | 140.70 | 0.34 | +0.2% | −84.5% | 0.3% | 1.4% | 0.00% |
 Sakar HealthcareSAKAR | 2,102 | 49.04 | 6.08 | +48.0% | +119.8% | 13.2% | 16.6% | 0.00% |
 Beta DrugsBETA | 2,000 | 36.99 | 4.57 | – | – | 16.4% | 14.2% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Fredun Pharmaceuticals dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹0.40 a share, year to Mar 2017.
| Ex-date | Type | Per share |
|---|---|---|
| 23 Jun 2026 | Final | ₹0.70 |
| 23 Sep 2025 | Final | ₹0.70 |
| 23 Sep 2024 | Final | ₹0.70 |
| 22 Sep 2023 | Final | ₹0.70 |
| 16 Sep 2021 | Final | ₹0.70 |
| 18 Sep 2020 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹0.66 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Fredun Pharmaceuticals announcements
Oct 2026
23 Oct · Board meeting
Meeting on 23 Oct 202623 Oct · Announcement under Regulation 30 (LODR)-Allotment
5 Oct · Announcement under Regulation 30 (LODR)-Allotment
Fredun Pharmaceuticals share price by year
Each calendar year to 2025.Fredun Pharmaceuticals share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025BSE close | 526.10 | +114.1% | 648.40 | 215.03 |
| 2024BSE close | 245.75 | −15.1% | 334.83 | 224.00 |
| 2023BSE close | 289.58 | −22.4% | 393.93 | 255.65 |
| 2022BSE close | 373.40 | +32.5% | 461.62 | 233.15 |
| 2021BSE close | 281.92 | +95.2% | 304.13 | 125.22 |
| 2020BSE close | 144.42 | +92.3% | 146.20 | 35.47 |
| 2019BSE close | 75.10 | −33.2% | 158.73 | 66.45 |
| 2018BSE close | 112.37 | +223.2% | 159.97 | 36.50 |
| 2017BSE close | 34.77 | +125.5% | 34.77 | 16.18 |
| 2016BSE close | 15.42 | – | 15.42 | 4.17 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2016 is from its first session, 28 Mar 2016.
Recent sessions
The 9 trading days to 29 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 29 Oct 2026 | 1,476.00 | 1,483.90 | 1,441.10 | 1,453.50 | 1,459.25 | 31,503 | 52.9% |
| 28 Oct 2026 | 1,471.00 | 1,481.00 | 1,438.00 | 1,472.20 | 1,465.85 | 43,696 | 49.4% |
| 27 Oct 2026 | 1,389.00 | 1,460.00 | 1,372.80 | 1,450.90 | 1,432.99 | 61,674 | 60.2% |
| 26 Oct 2026 | 1,368.40 | 1,381.50 | 1,345.80 | 1,365.50 | 1,363.02 | 23,889 | 34.9% |
| 23 Oct 2026 | 1,398.90 | 1,398.90 | 1,315.80 | 1,368.40 | 1,348.64 | 52,749 | 40.2% |
| 22 Oct 2026 | 1,353.20 | 1,400.00 | 1,353.20 | 1,391.00 | 1,380.71 | 38,003 | 47.7% |
| 21 Oct 2026 | 1,436.90 | 1,450.30 | 1,329.90 | 1,365.90 | 1,380.45 | 1,53,208 | 56.3% |
| 19 Oct 2026 | 1,461.30 | 1,482.00 | 1,406.00 | 1,438.40 | 1,443.00 | 93,163 | 51.7% |
| 16 Oct 2026 | 1,476.40 | 1,500.00 | 1,433.20 | 1,477.70 | 1,469.91 | 49,897 | 48.0% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Bonus share history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 16 Jul 2026 | Bonus | 0.3333 | Holders received 2 bonus shares for every 1 held. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout.
Company details
- NSE symbol
- FREDUN
- BSE code
- 539730
- ISIN
- INE194R01017
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.fredungroup.com
- CIN
- L24239MH1987PLC043662
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1987
- Registered office
- Tower A,, Urmi Estate 95, 11th Floor, Ganpatrao Kadam Marg, Lower Parel (W), Mumbai 400013, Maharashtra
- Share registrar
- Purva Sharegistry (India) Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments